Neoantigen-specific stem cell memory-like CD4(+) T cells mediate CD8(+) T cell-dependent immunotherapy of MHC class II-negative solid tumors

CD4(+) T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8(+) T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8(+) T cells capable of direct tumor recognition have been extensively studied, whereas the role of NeoAg-specific CD4(+) T cells is less well understood. We have characterized the murine CD4(+) T cell response against a validated NeoAg (CLTC(H129>Q)) expressed by the MHC-II-deficient squamous cell carcinoma tumor model (SCC VII) at the level of single T cell receptor (TCR) clonotypes and in the setting of adoptive immunotherapy. We find that the natural CLTC(H129>Q)-specific repertoire is diverse and contains TCRs with distinct avidities as measured by tetramer-binding assays and CD4 dependence. Despite these differences, CD4(+) T cells expressing high or moderate avidity TCRs undergo comparable in vivo proliferation to cross-presented antigen from growing tumors and drive similar levels of therapeutic immunity that is dependent on CD8(+) T cells and CD40L signaling. Adoptive cellular therapy (ACT) with NeoAg-specific CD4(+) T cells is most effective when TCR-engineered cells are differentiated ex vivo with IL-7 and IL-15 rather than IL-2 and this was associated with both increased expansion as well as the acquisition and stable maintenance of a T stem cell memory (T(SCM))-like phenotype in tumor-draining lymph nodes (tdLNs). ACT with T(SCM)-like CD4(+) T cells results in lower PD-1 expression by CD8(+) T cells in the tumor microenvironment and an increased frequency of PD-1(+)CD8(+) T cells in tdLNs. These findings illuminate the role of NeoAg-specific CD4(+) T cells in mediating antitumor immunity via providing help to CD8(+) T cells and highlight their therapeutic potential in ACT.